期刊
EXPERIMENTAL GERONTOLOGY
卷 46, 期 2-3, 页码 155-163出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.exger.2010.08.030
关键词
Rapamycin; TOR; Neurodegeneration; Alzheimer's disease; Huntington's disease; Parkinson's disease
资金
- NIA NIH HHS [T32 AG000057, AG033373-03, AG035336-02, R01 AG035336, T32 AG 00057, R01 AG033373] Funding Source: Medline
Signaling by target of rapamycin (mTOR in mammals) has been shown to modulate lifespan in several model organisms ranging from yeast to mice. In mice, reduced mTOR signaling by chronic rapamycin treatment leads to life span extension, raising the possibility that rapamycin and its analogs may benefit the aging brain and serve as effective treatments of age-related neurodegenerative diseases. Here, we review mTOR signaling and how neurons utilize mTOR to regulate brain function, including regulation of feeding, synaptic plasticity and memory formation. Additionally, we discuss recent findings that evaluate the mechanisms by which reduced mTOR activity might benefit the aging brain in normal and pathological states. We will focus on recent studies investigating mTOR and Alzheimer's disease, Parkinson's disease, and polyglutamine expansion syndromes such as Huntington's disease. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据